Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback